Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
audiogram
auditory and vestibular pathways
carbamazepine
dantrolene sodium
demyelinating disease
diet
dilantin
droperidol
fasciculation
genetic neurologic disorders
guanidine
hearing loss
hyperhidrosis
Isaacs syndrome
meclizine
multiple sclerosis
multiple sclerosis, diagnosis of
multiple sclerosis, diet in
multiple sclerosis, differential diagnosis of
multiple sclerosis, etiology of
multiple sclerosis, linoleic acid in
multiple sclerosis, treatment of
muscle atrophy, static
muscle pain
muscle stiffness
muscle weakness
myasthenic syndrome
myasthenic syndrome, treatment of
myokymia
neuromyotonia
neuropathy, peripheral
neurosyphilis
Parkinson disease
primrose oil
sinemet
steroid therapy, CNS treatment and complications with
sweating
sweating, abnormality of
syphilis, neurologic complications with
treatment of neurologic disorder
valium
vertigo
vertigo, cervical
vertigo, treatment of
Showing articles 550 to 600 of 4994 << Previous Next >>

Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007

What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007

Rehabilitation for Spatial Neglect Improves Test Performance But Not Disability
Stroke 38:2869-2870, Bowen,A. &Lincoln,N.B., 2007

Treatment of Physicians With Epilepsy
Neurol 69:1374-1379, Allen,J.W. &Devinsky,O., 2007

Parental Transmission of MS in a Population-Based Canadian Cohort
Neurol 69:1208-1212,1202, Herrera,B.M.,et al, 2007

Thalamic Atrophy and Cognition in Multiple Sclerosis
Neurol 69:1213-1223, Houtchens,M.K.,et al, 2007

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

Reduction in Neural-Tube Defects After Folic Acid Fortification in Canada
NEJM 357:135-142, De Wals,P.,et al, 2007

Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007

Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007

Long-Term Prognosis in Children With Neonatal Seizures: A Population-Based Study
Neurol 69:1816-1822, Ronen,G.M.,et al, 2007

Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007

Balos Concentric Sclerosis Presenting as a Stroke-Like Syndrome
Nat Clin Pract Neurol 3:349-354, Mowry,E.M.,et al, 2007

Asymmetric Cerebellar Ataxia and Limbic Encephalitis as a Presenting Feature of Primary Sjogrens Syndrome
J Neurol 254:1609-1611, Collison,K. and Rees,J., 2007

Course and Outcome of Acute Limbic Encephalitis With Negative Voltage-Gated Potassium Channel Antibodies
JNNP 78:391-394, Samarasekera,S.R., et al, 2007

CSF Analysis in Patients With Sporadic CJD and Other Transmissible Spongiform Encephalopathies
Eur J Neurol 14:121-124, Green,A.,et al, 2007

Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007

The Differential Diagnosis of Multiple Sclerosis
Neurologist 13:57-72, Rolak, L.A.,et al, 2007

Multiple Sclerosis After Infectious Mononucleosis
Arch Neurol 64:72-75, Nielsen,T.R.,et al, 2007

Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
JAMA 296:2832-2838, Munger,K.L.,et al, 2006

Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006

Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006

Multiple Sclerosis with and without CSF Bands:Clinically Indistinguishable but Immunogenetically Distinct
Neurol 67:1062-1064, Imrell,K.,et al, 2006

In Vivo Detection of Cortical Plaques by MR Imaging in Patients with Multiple Sclerosis
AJNR 27:2161-2167, Bagnato,F.,et al, 2006

Pathologic Laughing and Intractable Hiccups Can Occur Early in Multiple Sclerosis
Neurol 67:1684-1686, de Seze,J.,et al, 2006

High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006

Neuromyelitis Optica IgG Status in Acute Partial Transverse Myelitis
Arch Neurol 63:1398-1400, Scott,T.F.,et al, 2006

Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006

Obsessive-Compulsive Disorder
BMJ 333:424-429, Heyman,I.,et al, 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Does High-Field MR Imaging Have an Influence on the Classification of Patients with Clinically Isolated Syndromes According to Current Diagnostic MR Imaging Criteria for Multiple Sclerosis
AJNR 27:1794-1798, Wattjes,M.P.,et al, 2006

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006

Community-Acquired Bacterial Meningitis in Adults
NEJM 354:44-53, van de Beek,D.,et al, 2006

Baseline MRI Predicts Future Attacks and Disability in Clinically Isolated Syndromes
Neurol 67:968-972, Tintore,M.,et al, 2006

IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006

Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006

Cerebral Sinovenous Thrombosis in the Neonate
Arch Neurol 63:405-409, Fitzgerald,K.C.,et al, 2006

Brain Abnormalities in Neuromyelitis Optica
Arch Neurol 63:390-396, Pittock,S.J.,et al, 2006

Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006

Treatment of Low Back Pain by Acupressure and Physical Therapy: Randomised Controlled Trial
BMJ 332:696-698,680, Hsieh,L.L.-C.,et al, 2006

Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006

Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should be Treated at the Time of Diagnosis
Arch Neurol 63:614-619, Frohman,E.M.,et al, 2006

Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Arch Neurol 63:611-619, Pittock,S.J.,et al, 2006

Increase in Multiple Sclerosis Relapse Rate Following in vitro Fertilization
Neurol 66:1280-1281, Laplaud,D.-A.,et al, 2006

Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Stroke 37:1217-1220, Somerfield,J.,et al, 2006

Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006

MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006

Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006

Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006

Past Adult Lead Exposure is Linked to Neurodegeneration Measured by Brain MRI
Neurol 66:1476-1484,1464, Stewart,W.F.,et al, 2006



Showing articles 550 to 600 of 4994 << Previous Next >>